What is Eliquis “Glem(t) dose” supposed to mean?
“Glemt” isn’t a standard Eliquis dose term. People usually mean one of these:
- The prescribed Eliquis dose strength (for example, 2.5 mg or 5 mg).
- The dose schedule (twice daily, often written as “BID”).
- A specific patient situation that changes the dose (kidney function, age, body weight, or interacting medicines).
If you tell me what the prescription label says (exact wording) and the strength you have (2.5 mg or 5 mg tablets), I can help interpret it.
Typical Eliquis dosing (most common situations)
Eliquis (apixaban) is usually taken by mouth twice daily, but the exact dose depends on the reason it was prescribed:
Stroke prevention in atrial fibrillation (AFib)
- Commonly 5 mg twice daily.
- A lower dose of 2.5 mg twice daily is used when patients meet certain criteria (commonly includes age, body weight, and/or kidney function).
Treatment of DVT/PE (blood clots) and reduction of recurrence
- Treatment dosing and then longer-term dosing can differ.
- The dosing also depends on whether this is initial treatment vs prevention of recurrence.
If your question is about “2.5 mg vs 5 mg,” what changes the dose?
For AFib, clinicians reduce Eliquis to 2.5 mg twice daily when specific patient factors are present (commonly older age, lower body weight, and/or impaired kidney function). The exact criteria come from the prescribing information and your clinician’s assessment.
How to confirm the correct dose quickly
Check these items on your bottle or prescription:
- Tablet strength: 2.5 mg or 5 mg.
- Directions: “take __ mg by mouth twice daily” or similar wording.
- Any notes about AFib vs DVT/PE, or “kidney dose adjustment.”
If you paste the exact prescription directions (or upload the text), I’ll translate it into plain language.
Can you share a bit more so I can give the right Eliquis dose?
Reply with:
1) Your Eliquis strength (2.5 mg or 5 mg),
2) What it’s for (AFib, DVT, PE, post-surgery, etc.), and
3) Any key details from your label (age/weight/kidney issues, if mentioned).